Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA-Reference-Cited by-同舟云学术

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

Published:2015-07-24 Issue:7 Volume:10 Page:e0133968
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ferreira Alberto,Sagkriotis Alexandros,Olson Melvin,Lu Jingsong,Makin Charles,Milnes Fran

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. Mechanisms of age-related macular degeneration;J Ambati;Neuron,2012

2. Age-related macular degeneration: how science is improving clinical care. Interview by Marc E. Weksler;JS Sunness;Geriatrics,1998

3. Age-related macular degeneration;PT de Jong;N Engl J Med,2006

4. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis;AR Rudnicka;Ophthalmol,2012

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on the currently available pharmacotherapy for wet macular degeneration;Expert Opinion on Pharmacotherapy;2024-04-12

2. Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration;Ophthalmology Science;2024-03

3. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration;Eye;2024-01-26

4. Patterns of anti-vascular endothelial growth factor treatment for chorioretinal vascular diseases: Analysis of a nationwide claims database in Japan;Annals of Clinical Epidemiology;2024

5. Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting;Ophthalmology Retina;2023-10